201 related articles for article (PubMed ID: 17357282)
1. The effect of extracorporeal efferent detoxication (EED) methods inclusion in the severe community-acquired pneumonia (CAP) treatment.
Makarevich A; Pancratova J; Kyrkovsky V
Adv Med Sci; 2006; 51():73-87. PubMed ID: 17357282
[TBL] [Abstract][Full Text] [Related]
2. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
[TBL] [Abstract][Full Text] [Related]
4. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia.
Bruns AH; Oosterheert JJ; Prokop M; Lammers JW; Hak E; Hoepelman AI
Clin Infect Dis; 2007 Oct; 45(8):983-91. PubMed ID: 17879912
[TBL] [Abstract][Full Text] [Related]
5. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
[TBL] [Abstract][Full Text] [Related]
6. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
[TBL] [Abstract][Full Text] [Related]
7. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
8. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
10. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
12. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia.
Lee RW; Lindstrom ST
Respirology; 2007 Jan; 12(1):111-6. PubMed ID: 17207035
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
Rahav G; Fidel J; Gibor Y; Shapiro M
Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
[TBL] [Abstract][Full Text] [Related]
14. Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia.
Igonin AA; Armstrong VW; Shipkova M; Lazareva NB; Kukes VG; Oellerich M
Clin Biochem; 2004 Mar; 37(3):204-9. PubMed ID: 14972642
[TBL] [Abstract][Full Text] [Related]
15. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis.
Golub JE; Bur S; Cronin WA; Gange S; Sterling TR; Oden B; Baruch N; Comstock GW; Chaisson RE
Int J Tuberc Lung Dis; 2005 Apr; 9(4):392-7. PubMed ID: 15832463
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
17. Chest physical therapy for children hospitalised with acute pneumonia: a randomised controlled trial.
Paludo C; Zhang L; Lincho CS; Lemos DV; Real GG; Bergamin JA
Thorax; 2008 Sep; 63(9):791-4. PubMed ID: 18276723
[TBL] [Abstract][Full Text] [Related]
18. Plasma d-dimer levels increase with the severity of community acquired pneumonia.
Güneysel O; Pirmit S; Karakurt S
Tuberk Toraks; 2004; 52(4):341-7. PubMed ID: 15558356
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
20. Management of community-acquired pneumonia by trained family general practitioners.
Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S
Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
